BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V}

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (403)	3/6/2003 7:31:08 PM
From: EVENT HORIZON III	of 423

Hi Texas Dude, Looked over the technical's... First I would not state that VERS is behaving in any sort of extraordinary fashion. Since May of 2002 there has been significant resistance up around $11 & $12. Only twice breaking above that level to $13 to $14... The moving averages are of little consequence to this point...The stock is testing but has not clearly broken out above those levels in any discernable way. Using other technical indicators I would anticipate this recent move to be like the rest & I would trade it as such. IMO $10 has historically been supportive & I would not touch the stock in this trading pattern until it offered me good technical's at that level or below it to its most faviorable entry point of recent range $8. No offense but this is my take. I'm a trader first & I'm not kind to technical's one bit. I treat them like an enemy so to speak. Now all that said technical's are indicators of what has happened & slowly show anticipation of future events... The Wise investor gets in before the run so to speak so ideally one buys based on both factors.... The drug with results due this month is it a VERS drug or BSI's? Curious what drug being developed by GENE? Do you mean the one licensed by GENE? What Phase III results do we get this month? Clinicals were held where US EUROPE? Same as type of drug or market with unmet need? Was this the BSI This merger...Stock merger? Effective March 1, 2003 at 12:01 a.m. (Milan time), Biosearch merged into Versicor in a stock-for-stock exchange. As a result of the merger, Biosearch shareholders received 1.77 shares of newly-issued Versicor common stock in exchange for each Biosearch ordinary share. The new company has a total of 47.8 million shares outstanding, composed of 26.4 million outstanding Versicor shares of common stock and 21.4 million shares of Versicor common stock to be issued to Biosearch shareholders. Versicor was advised by Lehman Brothers and Biosearch was advised by SG Cowen and Livolsi & Partners. When will these shares be registered on the open market? I see VERS with 72 million in cash is their burn really 48 million...whew... Did BSI bring any cash to the situation & what was their burn. Granted their pipeline looks promising...Should be interesting... I typically avoid holding through Phase results just because of the risks...more fail than succeed...I usually trade the inbetween times. Enjoy Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next